Acute Angle-Closure Glaucoma — Emergency Management

Key Points

• Acute angle closure causes painful red eye plus visual loss and often nausea or vomiting; it is not routine conjunctivitis.
• Measure intraocular pressure and visual acuity promptly unless ocular trauma makes tonometry unsafe.
• Start multiple pressure-lowering mechanisms at once while obtaining urgent ophthalmology consultation.
• Acetazolamide is a standard systemic therapy unless contraindicated.
• Pilocarpine is usually given after pressure begins to fall and is not appropriate for every secondary angle-closure mechanism.
• Primary pupillary-block angle closure requires definitive laser peripheral iridotomy, not indefinite medical therapy.
• The fellow eye usually needs prophylactic evaluation and often iridotomy because anatomy is commonly bilateral.
• Topiramate-associated bilateral angle closure is caused by ciliochoroidal effusion and requires medication cessation and a different treatment approach.

Algorithm

1. Identify painful red eye with reduced vision, headache, halos, nausea, or a poorly reactive mid-dilated pupil.
2. Measure visual acuity, pupils, slit-lamp findings, and intraocular pressure while contacting ophthalmology.
3. Start topical beta blocker and alpha agonist plus systemic acetazolamide when safe.
4. Add hyperosmotic therapy for persistently severe pressure or inadequate initial response.
5. After pressure begins falling, use pilocarpine when primary pupillary block is the mechanism.
6. Recheck IOP and visual symptoms frequently and treat inflammation.
7. Perform definitive laser iridotomy for primary angle closure and address the fellow eye.
8. If mechanism is secondary, such as topiramate or neovascular disease, treat the underlying cause rather than applying the primary-angle pathway blindly.

Clinical Synopsis & Reasoning

The affected eye is often red with ciliary flush, markedly elevated intraocular pressure, corneal edema, shallow anterior chamber, and a mid-dilated pupil. Symptoms can mimic migraine, gastroenteritis, or neurologic disease because headache and vomiting may dominate. Measure visual acuity in each eye, inspect pupils, perform slit-lamp examination when available, and measure intraocular pressure unless globe rupture is suspected. Gonioscopy confirms angle closure once the cornea clears enough for specialist examination. Predisposing anatomy includes shallow anterior chambers and short axial length; risk rises with age and hyperopia. Pharmacologic dilation can precipitate an attack in susceptible eyes. Secondary angle closure from uveitis, lens disorders, neovascularization, tumor, or drugs such as topiramate requires a different mechanism-specific approach. Topiramate-associated bilateral acute myopia and angle closure is generally not treated with pilocarpine or routine iridotomy because the mechanism is ciliochoroidal effusion rather than pupillary block. Differential diagnosis includes anterior uveitis, keratitis, scleritis, conjunctivitis, endophthalmitis, and orbital disease. Severe eye pain with reduced vision is never simple conjunctivitis until dangerous causes are excluded.

Treatment Strategy & Disposition

Begin pressure-lowering therapy immediately while contacting ophthalmology. A common initial combination is topical timolol, topical alpha-2 agonist such as apraclonidine or brimonidine, and systemic acetazolamide if not contraindicated. Hyperosmotic therapy such as IV mannitol can be added for very high pressure or inadequate response, with caution in heart or kidney failure. Pilocarpine can help constrict the pupil after pressure has begun to fall, but at extremely high IOP the ischemic iris sphincter may not respond; it is avoided in mechanisms such as topiramate-induced angle closure. Topical corticosteroid can reduce anterior-segment inflammation. Definitive treatment for primary pupillary-block disease is laser peripheral iridotomy once the cornea is clear enough, with prophylactic treatment of the fellow eye because anatomic risk is often bilateral. If laser cannot be performed or fails, surgical iridectomy or lens-based intervention may be required. Stop an offending precipitating medication when secondary drug-induced closure is identified. Vision loss, optic-nerve damage, and peripheral anterior synechiae become more likely as high pressure persists, making same-day specialist treatment essential.

Epidemiology / Risk Factors

• Primary angle closure is more common with older age, hyperopia, female sex, and certain Asian and Inuit populations because of anatomic predisposition.
• The fellow eye commonly has similar narrow-angle anatomy.
• Episodes may be precipitated by dim light, emotional stress, or medications that cause pupillary dilation.
• Secondary angle closure can occur with uveitis, neovascular glaucoma, lens disorders, choroidal effusion, and several medications.
• Delayed treatment can cause permanent optic-nerve injury within a short period.

Investigations

Initial Medication Set (Example)

Pharmacology

Prognosis / Complications

• Visual outcome is excellent when pressure is reduced rapidly and definitive treatment is performed before optic-nerve damage.
• Longer duration and higher peak pressure increase the risk of permanent visual-field loss and glaucomatous neuropathy.
• Peripheral anterior synechiae can leave chronic angle closure even after the acute attack ends.
• The untreated fellow eye has substantial future attack risk in primary anatomic disease.
• Long-term ophthalmology follow-up remains necessary after iridotomy to monitor pressure and optic nerve health.

Patient Education / Counseling

• Explain that the pressure rise threatens vision and requires immediate treatment even if pain improves after initial drops.
• Attend definitive laser treatment and fellow-eye assessment as instructed.
• Review all medications with ophthalmology, especially topiramate and drugs with anticholinergic or adrenergic effects if narrow angles are known.
• Seek urgent eye care for recurrent halos, eye pain, blurred vision, headache with a red eye, or nausea associated with vision change.
• After iridotomy, continue scheduled glaucoma surveillance because pressure can remain elevated from chronic angle damage.

Notes

Acute angle closure is treated in two phases. The first phase is immediate pharmacologic pressure reduction so the cornea clears and the optic nerve is protected. The second is definitive correction of the anatomic mechanism, usually laser iridotomy in primary pupillary-block disease. Confusing these phases leads either to dangerous delay or to indefinite temporary therapy. The other critical distinction is primary versus secondary closure, because a drug-induced ciliochoroidal effusion, neovascular process, or uveitic mechanism cannot be managed safely by applying the same iridotomy-and-pilocarpine pathway to every patient.

References

1. American Academy of Ophthalmology EyeWiki: Primary vs Secondary Angle Closure Glaucoma — Link